File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients

TitleA double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients
Authors
KeywordsBehavioural and psychological symptoms
Dementia
Extrapyramidal symptoms
Haloperidol
Risperidone
Issue Date2001
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/4294
Citation
International Journal Of Geriatric Psychiatry, 2001, v. 16 n. 12, p. 1156-1162 How to Cite?
AbstractBackground: Behavioural and psychological (BPSD) are common during the course of dementia and present severe problems to patients and their caregivers. Objectives: To assess the therapeutic efficacy and safety of haloperidol and risperidone in treating BPSD in Chinese dementia patients. Methods: A 12-week double-blind randomised comparison of haloperidol and risperidone treatments was conducted in 58 patients with DSM-IV diagnosis of dementia of Alzheimer's type or vascular dementia. They were randomly assigned to receive flexible doses (0.5 to 2 mg/day) of haloperidol or risperidone. Clinical response was evaluated using the Cohen-Mansfield Agitation Inventory (CMAI), the Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), Simpson-Angus Scale, Functional Assessment Staging and Cantonese version of the Mini-Mental State Examination. Results: The mean doses at the last week were 0.90 mg/day of haloperidol and 0.85 mg/day of risperidone. Both haloperidol and risperidone significantly reduced the severity of BPSD (scores on CMAI an BEHAVE-AD), with no significant between-group differences. Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperodine-treated patients. Conclusions: Low-dose haloperidol and risperidone were well tolerated and associated with reductions in the severity and frequency of behavioural symptoms in subjects with dementia. Risperidone may have a more favourable risk-benefit profile in view of its lower propensity to induce extrapyramidal symptoms. Copyright © 2001 John Wiley & Sons, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/174234
ISSN
2023 Impact Factor: 3.6
2023 SCImago Journal Rankings: 1.187
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, WCen_US
dc.contributor.authorLam, LCWen_US
dc.contributor.authorChoy, CNPen_US
dc.contributor.authorLeung, VPYen_US
dc.contributor.authorLi, SWen_US
dc.contributor.authorChiu, HFKen_US
dc.date.accessioned2012-11-22T02:01:25Z-
dc.date.available2012-11-22T02:01:25Z-
dc.date.issued2001en_US
dc.identifier.citationInternational Journal Of Geriatric Psychiatry, 2001, v. 16 n. 12, p. 1156-1162en_US
dc.identifier.issn0885-6230en_US
dc.identifier.urihttp://hdl.handle.net/10722/174234-
dc.description.abstractBackground: Behavioural and psychological (BPSD) are common during the course of dementia and present severe problems to patients and their caregivers. Objectives: To assess the therapeutic efficacy and safety of haloperidol and risperidone in treating BPSD in Chinese dementia patients. Methods: A 12-week double-blind randomised comparison of haloperidol and risperidone treatments was conducted in 58 patients with DSM-IV diagnosis of dementia of Alzheimer's type or vascular dementia. They were randomly assigned to receive flexible doses (0.5 to 2 mg/day) of haloperidol or risperidone. Clinical response was evaluated using the Cohen-Mansfield Agitation Inventory (CMAI), the Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), Simpson-Angus Scale, Functional Assessment Staging and Cantonese version of the Mini-Mental State Examination. Results: The mean doses at the last week were 0.90 mg/day of haloperidol and 0.85 mg/day of risperidone. Both haloperidol and risperidone significantly reduced the severity of BPSD (scores on CMAI an BEHAVE-AD), with no significant between-group differences. Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperodine-treated patients. Conclusions: Low-dose haloperidol and risperidone were well tolerated and associated with reductions in the severity and frequency of behavioural symptoms in subjects with dementia. Risperidone may have a more favourable risk-benefit profile in view of its lower propensity to induce extrapyramidal symptoms. Copyright © 2001 John Wiley & Sons, Ltd.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/4294en_US
dc.relation.ispartofInternational Journal of Geriatric Psychiatryen_US
dc.subjectBehavioural and psychological symptoms-
dc.subjectDementia-
dc.subjectExtrapyramidal symptoms-
dc.subjectHaloperidol-
dc.subjectRisperidone-
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAlzheimer Disease - Diagnosis - Drug Therapy - Psychologyen_US
dc.subject.meshDementia, Vascular - Diagnosis - Drug Therapy - Psychologyen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHaloperidol - Adverse Effects - Therapeutic Useen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshRisperidone - Adverse Effects - Therapeutic Useen_US
dc.subject.meshSocial Behavior Disorders - Diagnosis - Drug Therapy - Psychologyen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleA double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patientsen_US
dc.typeArticleen_US
dc.identifier.emailChan, WC: waicchan@hku.hken_US
dc.identifier.authorityChan, WC=rp01687en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/gps.504en_US
dc.identifier.pmid11748775-
dc.identifier.scopuseid_2-s2.0-0035674311en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035674311&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue12en_US
dc.identifier.spage1156en_US
dc.identifier.epage1162en_US
dc.identifier.isiWOS:000173068000006-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridChan, WC=16400525900en_US
dc.identifier.scopusauthoridLam, LCW=7201984627en_US
dc.identifier.scopusauthoridChoy, CNP=18934166900en_US
dc.identifier.scopusauthoridLeung, VPY=7102336030en_US
dc.identifier.scopusauthoridLi, SW=7409240495en_US
dc.identifier.scopusauthoridChiu, HFK=7401986628en_US
dc.identifier.issnl0885-6230-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats